The effect of COVID-19 on nasal mucociliary clearance. 2022

Ebru Ozer Ozturk, and Mehmet Aslan, and Tuba Bayındır
Department of Otorhinolaryngology, Malatya Training and Research Hospital, Malatya, Turkey.

The impacts of coronavirus disease-2019 (COVID-19) on nasal mucociliary clearance (MCC) have shown conflicting results. The aim of this study was to determine whether COVID-19 infections affect nasal mucociliary activity using the saccharin test to measure nasal MCC time. This prospective comparative investigation included 25 patients with COVID-19 infection and 25 healthy controls. The nasal MCC time was assessed using the saccharin test. Saccharin test was applied to COVID-19 patients between the 10th and 20th days of COVID-19 test positivity. Patients admitted to the otolaryngology outpatient clinic with non-nasal symptoms and no history of COVID-19 infection served as the control subjects. Age, gender distribution, smoking, and alcohol usage, and the existence of other systemic disorders had no statistically significant differences between the groups (p = 0.25, p = 0.77, p = 1.00, p = 0.28, p = 0.54, respectively). The COVID-19 group had a mean nasal MCC time of 12.00 ± 2.51 min, compared to 9.77 ± 2.51 min in the control group. The nasal MCC time in the COVID-19 group was statistically significantly longer (p = 0.043). The COVID-19 infection negatively affects mucociliary activity and causes prolongation of MCC. As the nasal defense mechanism weakens in the early period after COVID-19 infection, susceptibility to respiratory infections may occur.

UI MeSH Term Description Entries
D009079 Mucociliary Clearance A non-specific host defense mechanism that removes MUCUS and other material from the LUNGS by ciliary and secretory activity of the tracheobronchial submucosal glands. It is measured in vivo as mucus transfer, ciliary beat frequency, and clearance of radioactive tracers. Mucociliary Transport,Clearance, Mucociliary,Clearances, Mucociliary,Mucociliary Clearances,Mucociliary Transports,Transport, Mucociliary,Transports, Mucociliary
D009297 Nasal Mucosa The mucous lining of the NASAL CAVITY, including lining of the nostril (vestibule) and the OLFACTORY MUCOSA. Nasal mucosa consists of ciliated cells, GOBLET CELLS, brush cells, small granule cells, basal cells (STEM CELLS) and glands containing both mucous and serous cells. Nasal Epithelium,Schneiderian Membrane,Epithelium, Nasal,Membrane, Schneiderian,Mucosa, Nasal
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000086382 COVID-19 A viral disorder generally characterized by high FEVER; COUGH; DYSPNEA; CHILLS; PERSISTENT TREMOR; MUSCLE PAIN; HEADACHE; SORE THROAT; a new loss of taste and/or smell (see AGEUSIA and ANOSMIA) and other symptoms of a VIRAL PNEUMONIA. In severe cases, a myriad of coagulopathy associated symptoms often correlating with COVID-19 severity is seen (e.g., BLOOD COAGULATION; THROMBOSIS; ACUTE RESPIRATORY DISTRESS SYNDROME; SEIZURES; HEART ATTACK; STROKE; multiple CEREBRAL INFARCTIONS; KIDNEY FAILURE; catastrophic ANTIPHOSPHOLIPID ANTIBODY SYNDROME and/or DISSEMINATED INTRAVASCULAR COAGULATION). In younger patients, rare inflammatory syndromes are sometimes associated with COVID-19 (e.g., atypical KAWASAKI SYNDROME; TOXIC SHOCK SYNDROME; pediatric multisystem inflammatory disease; and CYTOKINE STORM SYNDROME). A coronavirus, SARS-CoV-2, in the genus BETACORONAVIRUS is the causative agent. 2019 Novel Coronavirus Disease,2019 Novel Coronavirus Infection,2019-nCoV Disease,2019-nCoV Infection,COVID-19 Pandemic,COVID-19 Pandemics,COVID-19 Virus Disease,COVID-19 Virus Infection,Coronavirus Disease 2019,Coronavirus Disease-19,SARS Coronavirus 2 Infection,SARS-CoV-2 Infection,Severe Acute Respiratory Syndrome Coronavirus 2 Infection,COVID19,2019 nCoV Disease,2019 nCoV Infection,2019-nCoV Diseases,2019-nCoV Infections,COVID 19,COVID 19 Pandemic,COVID 19 Virus Disease,COVID 19 Virus Infection,COVID-19 Virus Diseases,COVID-19 Virus Infections,Coronavirus Disease 19,Disease 2019, Coronavirus,Disease, 2019-nCoV,Disease, COVID-19 Virus,Infection, 2019-nCoV,Infection, COVID-19 Virus,Infection, SARS-CoV-2,Pandemic, COVID-19,SARS CoV 2 Infection,SARS-CoV-2 Infections,Virus Disease, COVID-19,Virus Infection, COVID-19
D012439 Saccharin Flavoring agent and non-nutritive sweetener. Saccharin Calcium,Saccharin Sodium,Calcium, Saccharin

Related Publications

Ebru Ozer Ozturk, and Mehmet Aslan, and Tuba Bayındır
January 2021, The Journal of craniofacial surgery,
Ebru Ozer Ozturk, and Mehmet Aslan, and Tuba Bayındır
January 1990, Acta oto-laryngologica,
Ebru Ozer Ozturk, and Mehmet Aslan, and Tuba Bayındır
October 2022, Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India,
Ebru Ozer Ozturk, and Mehmet Aslan, and Tuba Bayındır
May 2006, Journal of clinical pharmacology,
Ebru Ozer Ozturk, and Mehmet Aslan, and Tuba Bayındır
December 2000, Clinical otolaryngology and allied sciences,
Ebru Ozer Ozturk, and Mehmet Aslan, and Tuba Bayındır
February 2001, Clinical otolaryngology and allied sciences,
Ebru Ozer Ozturk, and Mehmet Aslan, and Tuba Bayındır
June 1987, British journal of anaesthesia,
Ebru Ozer Ozturk, and Mehmet Aslan, and Tuba Bayındır
October 1988, The Journal of laryngology and otology,
Ebru Ozer Ozturk, and Mehmet Aslan, and Tuba Bayındır
February 2015, European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery,
Ebru Ozer Ozturk, and Mehmet Aslan, and Tuba Bayındır
November 2021, Acta oto-laryngologica,
Copied contents to your clipboard!